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Abstract
Background: Sarcopenia is increasingly recognized as a correlate of ageing and is associated with increased
likelihood of adverse outcomes including falls, fractures, frailty and mortality. Several tools have been recommended
to assess muscle mass, muscle strength and physical performance in clinical trials. Whilst these tools have proven to
be accurate and reliable in investigational settings, many are not easily applied to daily practice.
Methods: This paper is based on literature reviews performed by members of the European Society for Clinical and
Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) working group on frailty and sarcopenia. Face-to-face
meetings were afterwards organized for the whole group to make amendments and discuss further recommendations.
Results: This paper proposes some user-friendly and inexpensive methods that can be used to assess sarcopenia in
real-life settings. Healthcare providers, particularly in primary care, should consider an assessment of sarcopenia in
individuals at increased risk; suggested tools for assessing risk include the Red Flag Method, the SARC-F questionnaire,
the SMI method or different prediction equations. Management of sarcopenia should primarily be patient centered
and involve the combination of both resistance and endurance based activity programmes with or without
dietary interventions. Development of a number of pharmacological interventions is also in progress.
Conclusions: Assessment of sarcopenia in individuals with risk factors, symptoms and/or conditions exposing
them to the risk of disability will become particularly important in the near future.
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Background
The term sarcopenia was first coined by Rosenberg et al.
in 1989 [1] as a progressive loss of skeletal muscle mass
with advancing age. Since then, the definition has ex-
panded to incorporate the notion of impaired muscle
strength and/or physical performance. Currently, several
definitions of sarcopenia have been proposed [2–10] but
no consensus has yet been reached. Depending on the
definition used, the prevalence of sarcopenia is reported
to be up to 29 % for older community-dwelling adults
and up to 33 % for individuals living in long-term care
institutions [11, 12]. Sarcopenia is associated with
morbidity and mortality from linked physical disabil-
ity, falls, fractures, poor quality of life, depression and
hospitalization [13–19].
Current research is focusing on nutritional exercise/
activity based and other novel interventions for improv-
ing the quality and quantity of skeletal muscle in older
people. Some studies demonstrated that resistance training
combined with nutritional supplements can improve
muscle function [11, 20–22]. A number of pharmacological
interventions are in development but no single agent has
been shown to be clinically effective, without unwanted ef-
fects, in maintaining or increasing skeletal muscle mass or
function. With the prospect of effective interventions, the
identification and assessment of sarcopenia will become
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particularly important to prevent disability and other nega-
tive health outcome in the near future.
The challenge in clinical practice will be in the assess-
ment of sarcopenia to identify those who might benefit
most from these interventions. Among the l current defi-
nitions of sarcopenia [3, 7, 8], there is a general agreement
on the need for muscle mass measurement with varying
recommendations on the roles of muscle strength assess-
ment and/or physical performance. Currently, several well
validated tools exist to measure these parameters, which
have been reviewed recently [18, 23, 24]. Whereas they
have been used for sarcopenia case finding in the research
setting, their use is not always feasible in daily clinical
practice. The purpose of this paper is to discuss different
approaches in the assessment of sarcopenia and potential
management strategies in clinical practice.
Methods
As in previous initiatives and publications [25–35], the
European Society for Clinical and Economic Aspects of
Osteoporosis and Osteoarthritis (ESCEO) working group
on frailty and sarcopenia consists of clinical scientists
and experts in the field of musculoskeletal diseases. Differ-
ent members of the ESCEO working group were asked to
prepare a review of the literature on 1) the general tools
for the assessment of sarcopenia, both in research and in
clinic (CC); 2) the assessment of physical performance in
daily practice (MC); 3) the role of imaging in the diagnosis
of sarcopenia in daily practice (MV); 4) the role of bio-
chemical markers in the diagnosis of sarcopenia in daily
practice (EC) and 5) the role of primary versus secondary
care physicians in the evaluation of sarcopenia (AC). A
brief summary of the management of sarcopenia in daily
practice was also proposed and discussed. Randomized
controlled studies, prospective studies, systematic reviews
and meta-analyses published before September 2015 were
searched on PubMed and Embase using the following
search terms : 1) Sarcopenia, Clinical, Evaluation, As-
sessment, Management; 2) Physical function, Physical
performance, Gait, Walk, Walking, Strength; 3) Elderly,
Muscle mass, Sarcopenia, Dual x-ray absorptiometry/
DXA/DEXA, Computer tomography/CT, Magnetic res-
onance imaging/MRI, Bioelectrical impedance/BIA; 4)
Frailty, Sarcopenia, Biomarker, Biochemical marker, and 5)
Primary care, Specialist care, Secondary care, Sarcopenia,
Management, Screening, Questionnaire. Additional stud-
ies were identified by a manual search of bibliographic ref-
erences of relevant articles and existing reviews. Each
member prepared a list of the most important papers
based on their review of the literature and then made a set
of preliminary recommendations. The subsequent step
was a face-to-face meeting for the whole group to make
amendments and discuss further recommendations. The
plan of the manuscript was also discussed and shared
conclusions were reached. The views expressed in this art-
icle are the personal views of the authors and may not be
understood or quoted as being made on behalf of or
reflecting the position of the EMA or one of its commit-
tees or working parties.
Results
How to assess sarcopenia in clinical practice?
Despite a relatively large number of tools being available
to measure muscle mass, muscle strength and physical
performance [36, 37], some of them are likely to be of
greater validity and utility for the assessment of sarcope-
nia in clinical practice than in clinical research and are
summarised in Table 1. Whereas some biochemical
markers of muscle metabolism (e.g. activin, n-terminal
propeptide of procollagen III and myostatin) are being
investigated for their ability to indicate muscle mass or
strength, current data suggest that it is premature to rec-
ommend their use in daily practice [38].
Table 1 Applicability of the existing tools for the assessment of
muscle mass, muscle strength and physical performance in
research and clinical settings
Applicable in
research
settings
Applicable in
specialist clinical
settings
Applicable in
primary care
settings
Assessment of muscle mass
DXA +++ +++ +
Anthropometric
measurements
+ ++ ++
CT-scan +++ ++ +
MRI +++ ++ +
BIA ++ ++ +
Assessment of muscle strength
Handgrip strength +++ +++ +++
Lower limb muscle
strength
+++ ++ +
Repeated chair stands
test
+ + ++
Assessment of physical performance
Gait speed +++ +++ +++
Timed Up and Go test ++ + +
Balance test + + +
6-min walk test ++ + +
400 m walk test ++ + +
Stair climb test ++ + +
SPPB test +++ ++ +
SPPB Short Physical Performance Battery
Nb. The group has chosen to attribute to each tool +++ (best recommended
tool) or ++ (best alternative tool) or + (less recommended tool) based on the
availability and the costs of the tool, the required time for the examination
and the availability of robust cut-off points
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There are currently a number of approaches to the
definition of sarcopenia in clinical practice [3, 7, 36].
However, these are usually more suited to research stud-
ies than wider clinical practice. Additionally, some of the
available methodologies for the assessment of sarcopenia
utilise methods for measuring muscle mass, strength
and physical function that are more suited to secondary
care, than primary care settings. We therefore tabulated
our preferences according to feasibility, complexity, re-
quired time for the examination, availability of robust
cut-off points and cost, in each of these three contexts:
research, specialist settings and primary care (Table 1).
Assessment of muscle mass
The widespread use of magnetic resonance imaging
(MRI) and computed tomography (CT) scan for the
non-invasive assessment of muscle mass [39] is limited
in primary care settings by difficulties in access, costs,
the lack of portable equipment and the requirement of
highly specialized personnel.
Dual-energy x-ray absorptiometry (DXA) is a well-
established, low-radiation technique used to assess body
composition and provides reproducible estimates of ap-
pendicular skeletal lean mass [40, 41]. It is acknowledged
that the accuracy of DXA for assessing muscle mass in
people of different ages and different pathological condi-
tions may vary. Moreover, DXA (in contrast to CT-scan
and MRI) cannot assess intra-muscular fat, which turns
out to be of increasing importance in terms of the qual-
ity of muscle and associations with clinical outcomes.
Bearing these limitations in mind, DXA is still consid-
ered as the procedure of choice for routine clinical as-
sessment. Using DXA, appendicular skeletal lean mass
(ALM) is measured as the sum of the non-bone and
non-fat mass of the four limbs. To adjust for body size, a
skeletal muscle index (SMI) is derived as ALM/height2.
Thresholds of SMI at two standard deviations below the
mean SMI of young male and female reference groups
have been proposed as gender-specific cut-off points for
sarcopenia. This results in two thresholds, proposed by
the EWGSOP [3], the first of 5.5 kg/m2 for women and
7.26 kg/m2 [8] for men and the second of 5.67 kg/m2 for
women and 7.25 kg/m2 for men [42], depending on the
reference group on which these cut-off have been estab-
lished. Using a different approach, the FNIH sarcopenia
project [7] has also recently defined cut-offs for appen-
dicular lean mass adjusted for body mass index (BMI),
giving values of < 0.512 for women and < 0.789 for men.
However, it should be pointed that these cut-offs might
also be modified according to ethnicity [43].
If clinicians have no access to DXA, they can use an-
thropometric measurements. Indeed, a recent survey
[44] showed that anthropometric data are currently the
most widely used methods in clinical practice (57.5 % of
clinicians that measure muscle mass in their practice use
anthropometric data) followed by DXA (45.9 %). Several
anthropometric measurements exist (i.e. body mass
index, calf circumference, mid-upper arm circumference
and skinfold thickness). Moreover, mid-arm muscle and
calf circumferences have been shown to be correlated
with appendicular muscle mass and reflect both health
and nutritional status and predict performance, health
and survival in older people [45–47]. However, with ad-
vancing age, changes in the distribution of fat and loss
of skin elasticity are such that circumference and skin-
fold measures incur a loss of accuracy and precision in
older people [47, 48]. Some studies suggest that an adjust-
ment of anthropometric measurements for age, sex or
BMI results in a better correlation with DXA-measured
lean mass [49–51]. Anthropometric measurements are
simple clinical prediction tools that can be easily applied
for sarcopenia since they offer the most portable, com-
monly applicable, inexpensive and non-invasive technique
for assessing size, proportions and composition of the hu-
man body [50]. However, their validity is limited when ap-
plied to individuals due to large prediction errors and
because cut-off points, to identify low muscle mass, still
need to be defined. Therefore, if a patient is identified as
at risk of having sarcopenia by anthropometric measure-
ments, an additional measurement of muscle mass with
DXA would still be recommended.
Finally, bio-electrical impedance analysis (BIA) is a
method which estimates the volume of fat and lean body
mass based on the relationship between the volume of a
conductor and its electrical resistance. The method is
not expensive, requires no specialized staff and is relatively
easy to use in clinical practice, both on ambulatory sub-
jects or on hospitalized patients. Moreover, reference
values have been established for older individuals [3]. Even
if the method’s accuracy has been challenged and has been
reported to overestimate muscle mass and underestimate
fat mass [52–54], it is possible to use some adjustment
equations to obtain valid measurements [55].
In summary, we would propose assessing primarily
muscle mass by DXA, if this tool is available, and if
not, anthropometry measurements can easily be used,
in primary care settings, as a first screening of patients
with low muscle mass. These patients can then be
referred for an additional evaluation in specialist
clinical settings.
Assessment of muscle strength
Handgrip strength appears to be the most widely used
method for the measurement of muscle strength. A recent
survey indicated that clinicians, both from the fields of
geriatric medicine and rheumatology, prefer the use of
grip strength over chest press and lower limb isokinetic
Beaudart et al. BMC Geriatrics  (2016) 16:170 Page 3 of 10
dynamometry as a measure of overall muscle strength
[44]. In general, isometric handgrip strength shows a good
correlation with leg strength [56] and also with lower ex-
tremity power, knee extension torque and calf cross-
sectional muscle area [15, 57]. The measurement is easy
to perform, inexpensive and does not require a specialist
trained staff. Standardized conditions for the test [58] in-
clude seating the subject in a standard chair with their
forearms resting flat on the armchairs. Clinicians should
demonstrate the use of the dynamometer and show that
gripping very tightly registers the best score. Six measures
should be taken, 3 with each arm. Ideally, the patients
should be encouraged to squeeze as hard and as tightly as
possible during 3–5 seconds for each of the 6 trials; usu-
ally the highest reading of the 6 measurements is reported
as the final result. The Jamar dynamometer, or similar hy-
draulic dynamometer, is the gold standard for this meas-
urement. However, for patients with advanced arthritis,
the design of this dynamometer may be a limitation [59].
A pneumatic dynamometer, such as the Martin vigorimeter,
may be a good alternative. With this device, patients try to
squeeze rubber balls (available in three sizes) with the same
protocol as that used for the Jamar dynamometer. A variety
of thresholds of grip strength have been proposed to
characterize low muscle strength, ranging from 16 to 20 kg
for women and 26–30 kg for men [7, 15, 60, 61]. Lower
limb muscle strength, most frequently of the quadriceps,
can also be measured. Commercial dynamometers can en-
able isometric and/or isokinetic measurements of strength.
Even if these measurements are feasible in frail people
[62, 63], they are often limited in clinical practice by
their relative expense, the need to purchase dedicated
equipment, the lack of trained staff and limited data in
older populations. However, the repeated chair stand
test, which is a timed test requiring participants to rise
from a chair without using their arms and return to the
seated position, consecutively, for five times, has been
shown to be able to provide a reasonably reliable and
valid indication of lower body strength [64].
In summary, we would recommend to measure muscle
strength by handgrip strength in clinical practice
(Table 1). For primary care settings where the
availability of a handgrip dynamometer is not
systematic, the repeated chair stand test could be used
as an alternative measure of muscle strength.
Assessment of physical performance
The most widely used tool in clinical practice for the as-
sessment of physical performance is the gait speed meas-
urement, employed by almost two-thirds (63.3 %) of
clinicians that assess physical performance (among 255
clinicians who took part in an international online sur-
vey; 87.8 % of medical doctors with geriatrics (57.6 %)
and rheumatology (18.8 %) as major fields of interest)
[44]. The test is highly acceptable for participants and
health professionals in clinical settings [65]. No special
equipment is required as it only needs a flat floor devoid
of obstacles. In the 4-m gait speed test, which is recom-
mended by the EWGSOP for the assessment of sarcopenia,
men and women with a gait speed <0.8 m/s are described
as having a poor physical performance [15]. The average
extra-time added to the consultation by measuring the
4-metre gait speed was only 95 ± 20 s.
Gait speed can be performed alone or as part of a test
battery, the most popular of which is the Short Physical
Performance Battery (SPPB). The SPPB is a test scored
to a maximum of 12 points comprising an assessment of
gait speed (over 3–4 m), a balance test and a repeated chair
stand test. These tests focus on lower extremity function, as
the latter has been shown to correlate with mobility, dis-
ability and patient outcomes including hospitalization,
institutionalization, and mortality. The SPPB takes about
10 min to complete [66]. Participants presenting a score ≤8
points have been described as having a poor physical
performance [3].
Other standalone tests can be performed to assess
physical performance. In the Timed Up and Go (TUG)
test, individuals are asked to rise from a standard arm-
chair, walk to a marker 3 m away, turn, walk back and
sit down again. The 6-min walk distance or 400 m walk
time can be used to measure aerobic capacity. The stair
climb power test also shows good correlation with other
measures of leg power and physical performance, but is
mostly restricted to use in research settings [67].
In summary, we would propose that physical
performance is primarily assessed in clinical practice
by measuring gait speed. The SPPB test may be
limited by the time of administration but might also
be useful to identify men and women with low
physical performance (Table 1).
The role of primary care physicians
In view of the current lack of a consensus concerning
the definition of sarcopenia and also of the practical is-
sues related to time constraints and limited access to as-
sessment tools in the primary care setting, the group
believes that the role of primary care physicians should
be to identify patients who are at risk of sarcopenia and
to refer them to specialists in the field. Some interesting
methods that might be suitable for screening purpose
are presented in the following section.
Consideration of possible sarcopenia should be under-
taken in older individuals (e.g. > 65 years) with signs or
symptoms suggestive of the condition both in primary
care and in specialized clinical settings. Several methods
can be proposed to perform a simple, rapid and inexpensive
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identification of those at risk. However, none of them has
received an extensive validation, and therefore further re-
search in this area is urgently needed.
The red flag method
The purpose of the red flag method is to understand,
during a standard medical consultation (or health assess-
ment) the clinical presentation of individuals with particu-
lar regard to physical manifestations of sarcopenia such as
general weakness or loss of muscle mass. The subject can
also be asked about symptoms such as loss of weight, loss
of muscle strength, loss of energy, falls, etc. (Table 2). An
assessment of nutrition habits should also be performed to
check, for example, if the subject has sufficient protein in-
take. The Mini-Nutritional Assessment could also be used
for a rapid and easy assessment of malnutrition or, at least,
risk of malnutrition [68]. Finally, clinicians can also assess
physical activity. Indeed physical inactivity or high levels of
sedentary behaviour may be considered a red flag. If the
screening identifies any red flag suggesting the presence of
sarcopenia, more sophisticated assessment procedures of
sarcopenia can be implemented. Red flags have been iden-
tified through reviewed papers identified by members of
the group and are presented in Table 2.
The SARC-F questionnaire
The SARC-F questionnaire [69] was developed as a pos-
sible rapid screening test for sarcopenia. This question-
naire could enable healthcare providers to quickly and
easily assess the risk of sarcopenia during a standard
health consultation. The subject is asked 5 questions ad-
dressing strength, assistance in walking, rising from a
chair, stair climbing and falls. Each component is scored
from 0 to 2 points, giving a global score of the SARC-F
between 0 and 10 points. A score ≥ 4 points is reported
to be predictive of sarcopenia and poor outcomes and
could be a trigger for a more detailed assessment of
sarcopenia.
Despite a questionable sensitivity [70], the SARC-F
questionnaire is considered as one of the best available
tools to be used in primary care for raising awareness of
the diagnosis of sarcopenia. Similarly to the red flag
method, a result ≥ 4 for the SARC-F questionnaire could
be an incentive to send the subject to a complete assess-
ment of sarcopenia.
Prediction of low muscle mass according to age and BMI
Recently, a study [71] has been performed with the pur-
pose to identify predictors of low skeletal muscle mass
in older adults toward development of a practical clinical
assessment tool for use by clinicians to identify individ-
uals requiring DXA screening for muscle mass. For this
purpose, ALM was calculated from DXA scans and SMI
defined as the ratio of ALM divided by height in square
centimetres. Older participants (from 65 to 85 years)
were classified has having low muscle mass if their SMI
was 1 standard deviation below the mean SMI of young
adults. This model was validated on a sample of 200
subjects of the NHANES population. Results of the val-
idation analysis revealed that age and BMI were strongly
associated with a low SMI and may be an informative
predictor in the primary care settings. Consequently, two
models were proposed, one for men and one for women
and consist of two tables presenting the probability of low
muscle mass by age and BMI. In a 200-person validation,
the model sensitivity was 81.6 % for men and 90.6 % for
women and the model specificity was 66.1 % for men and
66.2 % for women.
Anthropometric prediction equation in combination with a
measure of muscle function
Other authors developed gender specific anthropometric
equations, based on age, weight, BMI values, to estimate
appendicular skeletal muscle mass [72]. To validate these
prediction equations, muscle mass was assessed using DXA
in three cohorts of older Australian subjects [72] (ap-
pendicular skeletal muscle mass prediction equation:
10.05 + 0.35(weight) − 0.62(BMI) − 0.02(age) + 5.10 (if
male)). The results showed a strong correlation be-
tween the equations and the muscle mass measured
using DXA, with an adjusted R2 of 0.869. In a subsequent
research the prediction equations were evaluated in com-
bination with assessment of hand grip strength as a
screening method to identify older patients who should
undergo DXA evaluation for sarcopenia. The best strategy
to reduce the number of DXA was to apply the equation
Table 2 The Red Flag method
Red flags
Clinician’s observation General weakness of the subject
Visual identification of loss of muscle mass
Low walking speed
Subject’s presenting
features
Loss of weight
Loss of muscle strength, in arms or in legs
General weakness
Fatigue
Falls
Mobility impairment
Loss of energy
Difficulties in physical activities or activities
of daily living
Clinician’s assessment Nutrition
Body weight
Physical activity
Nb. Red flags have been identified through reviewed papers identified by
members of the group
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first, to assess hand grip strength in those with low es-
timated muscle mass and to proceed to DXA only in
individuals with low grip strength [50].
Prediction of sarcopenia using age, handgrip strength and
calf circumference
In 2014, Ishii et al. [73] developed a new screening tool
for sarcopenia in a sample of almost 2000 autonomous
community-dwelling older subjects in Japan. Sarcopenia
was defined on the basis of low muscle mass measured
by BIA and either low muscle strength characterized by
handgrip or low physical performance characterized by
slow gait speed. Using a database including demographic
variables, albumin, chronic diseases, physical activity infor-
mation and anthropometric measurements, the authors de-
veloped a gender specific model including three variables,
i.e. age, handgrip strength and calf circumference. Based on
the model, the authors constructed a gender specific score
chart that had an excellent discrimination ability, with an
area under the curve of 0.939 for men and 0.909 for
women. The formula to calculate the scores are as follows:
score in men, 0.62 x (age-64) – 3.09 x (grip strength −50) –
4.64 x (calf circumference −42); score in women, 0.80 x
(age-64) – 5.09 (grip strength −34) – 3.28 x (calf circumfer-
ence – 42). The corresponding probabilities of sarcopenia
were calculated as: probability in men, 1 / [1 + e-(sum score/
10–11.9)]; probability in women, 1/[1 + e -(sum score/10–12.5)].
This model still requires further validation in independent
cohorts, before its use in clinical practice can be promoted.
How to manage sarcopenia in daily practice?
Identification of comorbidities
Sarcopenia is frequently found in association with co-
morbidities, e.g. osteoporosis, osteopenia, obesity, type II
diabetes mellitus, breast cancer, etc. [74, 75]. In such
cases, sarcopenia may be considered as a secondary con-
sequence of the co-existing pathological condition. The
impact of management of these conditions (e.g. better
diabetic control, reduction of inflammatory status, or
weight loss in obesity due to an energy-restricted diet)
on the accompanying sarcopenia is unclear [76].
Physical activity
Physical activity interventions and progressive resistance
training have been suggested to have a predominant
effect on muscle strength, muscle mass and physical
performance in older people [77].
However, so far, studies mainly focusing on well-
defined sarcopenia with standardization of the physical
intervention are still missing. Hence, it is still difficult to
give a patient-specific physical activity prescription for the
management of sarcopenia. However, healthcare providers
can nevertheless give some general recommendations in
order to improve other common conditions in older
adults (WHO recommendation: http://www.who.int/diet-
physicalactivity/factsheet_olderadults/en/). Moreover, in
their review, Cruz Jentoft at al [11]. forwarded two recom-
mendations regarding the management of physical activity
interventions in older people. First, to obtain an impact on
muscle function, the duration of the intervention should
be for at least 3 months. Second, supervised resistance
exercise or multicomponent/combined exercise pro-
grams should be recommended for frail or sedentary
community-dwelling people.
Nutrition
Although nutrition is considered as a major point for
the management of sarcopenia, evidence of the effect of
nutrition on muscle function is often derived from
short-term studies in specifically selected sample and
large clinical trials are still lacking. Currently, there is no
robust evidence for nutritional recommendations for
subjects with sarcopenia.
However, even if randomized controlled trials are incon-
sistent regarding the effects of protein supplementation on
muscle function, several observational studies have sug-
gested that maintaining adequate protein intake may help
preserve muscle mass and strength in both adults and
older people [78, 79]. Bauer et al. [80] recommended in-
creasing protein intake to 1.2 g/kg body weight/day either
by diet or by protein supplementation in older adults be-
cause of blunted muscle protein synthetic response and
blunted post-prandial inhibition of muscle protein break-
down (anabolic resistance). Frail older adults or older who
have acute or chronic diseases need higher dietary protein
(i.e. 1.2–1.5 g/kg body weight/d) [80]. Recent evidence
suggests that the recommended dietary allowance for pro-
tein is inadequate in older people [81]. Some other nutri-
tional supplements, such as β-hydroxy β-methylbutyrate,
creatine and vitamin D have been suggested to have an
effect on muscle function. Indeed, β-hydroxy β-
methylbutyrate supplements appear to increase muscle
mass whilst its effects on muscle strength and physical
performance are inconsistent [11, 20, 21]. Supplementa-
tion with creatine, protein or leucine combined with re-
sistance exercises seems to have a positive impact on
muscle mass, muscle strength and physical performance
[22, 82, 83]. Finally, a recent meta-analysis has suggested
that vitamin D supplementation could increase lower limb
muscle strength [84]. Based on this evidence, dietary pro-
tein caloric intake, protein quality, as well as the vitamin
D status of older individuals could be checked by clini-
cians and/or dieticians and individual prescription of
nutritional supplements could be considered.
Pharmacological management
Currently, no drug is registered for the treatment of
sarcopenia. However, several new chemical entities are
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currently at various stages of development. These are
summarized in Table 3 with their potential future indi-
cations and their current phase of development.
Discussion and general consensus
The ESCEO Experts group agreed on some general rec-
ommendations to be implemented in clinical practice:
– Several tools are currently available for the
measurement of muscle mass, muscle strength and
physical performance, with a potential use for the
diagnosis and follow-up of sarcopenia but they are
not fully adapted for widespread use in clinical daily
practice. The recommended tools for the diagnosis
of sarcopenia in specialist clinical practice are DXA
for the measurement of appendicular muscle mass,
grip strength for the measurement of muscle strength
and gait speed for the measurement of physical
performance. Thresholds previously recommended
in the literature can be applied to distinguish normal
from abnormal;
– Healthcare providers, particularly in primary care,
should consider an assessment of sarcopenia in
individuals at increased risk; suggested tools for
assessing risk include the SARC-F questionnaire,
the SMI method or different prediction equations
based on anthropometric data associated with the
measurement of handgrip strength, although all of
them require further validation;
– Whereas further studies are required to provide a
full evidence-based guidance to clinicians, current
management can include physical activity advice,
particularly progressive resistance training, treatment
and prevention of vitamin D deficiency and adequate
energy and dietary protein intake.
The Expert group also emphasizes the importance of
education and increased awareness of clinicians to the
potential deleterious outcomes of sarcopenia.
Conclusions
Physicians and other health professionals have an im-
portant role to play in the assessment and management
of sarcopenia to reduce its impact on individuals’ well-
being, the development of disability, and on health re-
sources utilization.
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